B-cell antigen D8/17 is a marker of rheumatic fever susceptibility in Aboriginal Australians and can be tested in remote settings

Medical Journal of Australia

Volumn 184, Issue 10, 2006, Pages 507-510

  Harrington, Zinta ^a   Visvanathan, Kumar ^b,c   Skinner, Narelle A ^c   Curtis, Nigel ^b   Currie, Bart J ^a,d   Carapetis, Jonathan R ^a,b,c  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; B LYMPHOCYTE ANTIGEN D17; B LYMPHOCYTE ANTIGEN D8; CD19 ANTIGEN; UNCLASSIFIED DRUG;

ABORIGINE; ACCURACY; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; AUSTRALIA; B LYMPHOCYTE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DISEASE MARKER; DISEASE PREDISPOSITION; FEASIBILITY STUDY; FEMALE; FLOW CYTOMETRY; HEALTH CARE ACCESS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PEDIATRIC HOSPITAL; PERIPHERAL BLOOD MONONUCLEAR CELL; REFERENCE VALUE; RELIABILITY; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; RURAL POPULATION; TERTIARY HEALTH CARE;

EID: 33646686877     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2006.tb00345.x     Document Type: Article

References (24)

1. Cheadle W. Harbeian lectures on the various manifestations of the rheumatic state as exemplified in childhood and early life. Lancet 1889; 3426: 821-827.
2. Davies A, Lazarov E. Heredity, infection and chemoprophylaxis in rheumatic carditis: an epidemiologic study of a communal settlement. J Hygiene 1960; 58: 263-269.
3. Taranta A, Torosdag S, Metrakos J, et al. Rheumatic fever in monozygotic and dizygotic twins [abstract]. Circulation 1959; 20: 778.
4. DiSciascio G, Taranta A. Rheumatic fever in children. Am Heart J 1980; 99: 635-658.
5. Quinn R. Comprehensive review of morbidity and mortality trends for rheumatic fever, streptococcal disease and scarlet fever: the decline of rheumatic fever. Rev Infect Dis 1989; 11: 928-953.
6. Weidebach W, Goldberg A, Chiarella J, et al. HLA Class II antigens in rheumatic fever. Analysis of the DR locus by restriction fragment-length polymorphism and oligotyping. Hum Immunol 1994; 40: 253-258.
7. Guedez Y, Kotby A, El-Demellawy M, et al. HLA class II associations with rheumatic heart disease are more evident and consistent among clinically homogenous patients. Circulation 1999; 99: 2784-2790.
8. Visentainer J, Pereira F, Dalalio M, et al. Association of HLA-DR7 with rheumatic fever in the Brazilian population. J Rheumatol 2000; 27: 1518-1520.
9. Khanna A, Buskirk D, Williams R, et al. Presence of a non-HLA B cell antigen in rheumatic fever patients and their families as defined by a monoclonal antibody. J Clin Invest 1989; 83: 1710-1716.
10. Herdy G, Zabriskie J, Chapman F, et al. A rapid test for the detection of a B-cell marker (D8/17) in rheumatic fever patients. Brazil J Med Biol Res 1992; 25: 789-794.
11. Harel L, Zeharia A, Kodman Y, et al. Presence of the D8/17 B-cell marker in children with rheumatic fever in Israel. Clin Genet 2002; 61: 293-298.
12. Kaur S, Kumar D, Grover A, et al. Ethnic differences in expression of susceptibility marker(s) in rheumatic fever/rheumatic heart disease patients. Int J Cardiol 1998; 64: 9-14.
13. Taneja V, Mehra N, Reddy K, et al. HLA-DR/DQ antigens and reactivity to B cell alloantigen D8/17 in Indian patients with rheumatic heart disease. Circulation 1989; 80: 335-340.
14. Ganguly N, Anand I, Koicha M, et al. Frequency of D8/17 B lymphocyte alloantigen in north Indian patients with rheumatic heart disease. Immunol Cell Biol 1992; 70: 9-14.
15. Anonymous. Strategy for controlling rheumatic fever/rheumatic heart disease, with emphasis on primary prevention: memorandum from a joint WHO/ISFC meeting. Bull World Health Organ 1995; 73: 583-587.
16. Edmond K, Noonan S, Krause V, et al. The Top End rheumatic heart disease control program II. Rates of rheumatic heart disease and acute rheumatic fever. Northern Territory Dis Control Bull 2001; 8: 18-22.
17. Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. JAMA 1992; 268: 2069-2073.
18. Chapman F, Visvanathan K, Carreno-Manjarrez R, Zabriskie J. A flow cytometric assay for D8/17 B cell marker in patients with Tourette's syndrome and obsessive compulsive disorder. J Immunol Methods 1998; 219: 181-186.
19. Gibofsky A, Khanna A, Suh E, Zabriskie J. The genetics of rheumatic fever: relationship to streptococcal infection and autoimmune disease. J Rheumatol 1991; 30 Supp 1: 1-5.
20. Feldman B, Zabriskie J, Silverman E, Laxer R. Diagnostic use of B-cell alloantigen D8/17 in rheumatic chorea. J Pediatr 1993; 123: 84-86.
21. Weisz J, McMahon W Moore J, et al. D8/17 and CD19 expression on lymphocytes of patients with acute rheumatic fever and Tourette's disorder. Clin Diagn Lab Immunol 2004; 11: 330-336.
22. Kemeny E, Husby G, Williams R, Zabriskie JB. Tissue distribution of antigen(s) defined by monoclonal antibody D8/17 reacting with B lymphocytes of patients with rheumatic heart disease. Clin Immunol Immunopathol 1994; 72: 35-43.
23. Zemel L, Hakonarson H, Diana D, Zabriskie J. Poststreptococcal reactive arthritis (PRSA): a clinical and immunogenetic analysis [abstract]. J Rheumatol 1992; 19 Suppl 33:120.
24. Carreno-Manjarrez R, Viteri-Jackson A, Visvanathan K, Zabriskie J. Characterization of B-cell marker D8/17. In: Martin DR, Tagg JR, editors. Streptococci and streptococcal diseases: entering the new millennium. Proceedings of the XIV Lancefield International Symposium on Streptococci and Streptococcal Diseases, 1998. Auckland, New Zealand: Securacopy, 2000: 529-532.